Eryaspase

Published

dm+d

Unassigned

New Medicines

Graspa (EU), Eryasp (US) Hypersensitive acute lymphoblastic leukaemia (ALL)

Information

Graspa (EU), Eryasp (US)
New molecular entity
ERYtech Pharma
ERYtech Pharma

Development and Regulatory status

None
None
Phase II Clinical Trials
Yes
Yes

Category

Asparagine modulators
ALL is the most common cancer in children. Global incidence is about 3 per 100,000 population, with about 3 out of 4 cases occurring in children aged under 6 years [2].
Hypersensitive acute lymphoblastic leukaemia (ALL)
Intravenous

Graspa (EU), Eryasp (US)Pancreatic cancer - second- line as add on to standard of care treatment

Information

Graspa (EU), Eryasp (US)
New molecular entity
ERYtech Pharma
ERYtech Pharma

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Oct 21Following failure of PIII pivotal trial to meet primary endpoint the continued development of eryaspase for pancreatic cancer is uncertain [11].

Category

Asparagine modulator, aimed at targeting cancer cells altered amino acid metabolism. The product is encapsulated inside donor-derived red blood cells.
There are approximately 150,000 new cases of pancreatic cancer diagnosed each year in US and Europe. Pancreatic cancer has a five-year survival rate of < 10% and is one of the fastest growing cancer indications, and the 4th leading cause of cancer deaths in the US [1].
Pancreatic cancer - second- line as add on to standard of care treatment
Intravenous

Further information

Yes

Trial or other data

Oct 21Erytech announce that PIII TRYbeCA-1 trial did not meet its primary endpoint of overall survival vs. chemotherapy alone (7.5 months vs 9.7 months; HR 0.92; 95% CI[ 0.76 to 1.11], p=0.375). A prespecified subgroup of patients treated with eryaspase and an irinotecan-based chemotherapy demonstrated an interesting trend of survival benefit, which Erytech note merits further investigation. However, for now the company will shift focus to developing therapy in ALL [11, 12].

Evidence based evaluations

Graspa (EU), Eryasp (US) Triple-negative breast cancer - first-line with chemotherapy

Information

Graspa (EU), Eryasp (US)
Licence extension / variation
ERYtech Pharma
ERYtech Pharma

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

Asparagine modulator, aimed at targeting cancer cells altered amino acid metabolism. The product is encapsulated inside donor-derived red blood cells.
Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells do not have estrogen or progesterone receptors and also do not make too much of the protein called HER2 [1].
Triple-negative breast cancer - first-line with chemotherapy
Intravenous infusion